The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Advanced Hypertensive Heart Disease in Spontaneously Hypertensive Rats: Lisinopril-Mediated Regression of Myocardial Fibrosis
Abstract
Left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHR) is accompanied by a structural remodeling of the myocardium that includes myocyte hypertrophy and interstitial and perivascular fibrosis of intramyocardial coronary arteries. The structural abnormalities related to fibrous tissue accumulation lead to increased myocardial diastolic stiffness and ultimately impaired systolic function of the left ventricle. It has been shown in 14-week-old SHR with early hypertensive heart disease that myocardial fibrosis could be reversed and myocardial diastolic stiffness normalized by 12-week treatment with the angiotensin-converting enzyme inhibitor lisinopril. Whether such functional defects of the myocardium, based on adverse structural changes, are also reversible in advanced hypertensive heart disease has been questioned. Therefore, we treated 78-week-old male SHR that had chronic hypertension and advanced LVH with severe myocardial fibrosis and age- and sex-matched normotensive Wistar-Kyoto rats (WKY) with 20 mg/kg per day oral lisinopril for 8 months. Compared with untreated SHR or WKY, we found the following: (1) Systolic arterial pressure was normalized ( P <.025) and LVH completely reversed ( P <.025) in SHR, with no significant reduction in systolic arterial pressure or left ventricular mass in WKY; (2) morphometrically determined myocardial fibrosis in SHR was significantly reversed ( P <.025) and associated with improved diastolic stiffness ( P <.05), which was measured in the isolated heart by calculation of the stiffness constant of the myocardium; no significant changes occurred in WKY; (3) reversal of myocardial fibrosis was accompanied by an increase ( P <.025) in myocardial matrix metalloproteinase 1 activity determined by degradation of [ 14 C]collagen with myocardial tissue extracts after trypsin activation of myocardial promatrix metalloproteinase 1; matrix metalloproteinase 1 activity remained unchanged in WKY treated with lisinopril; and (4) systolic dysfunction, measured by a significantly ( P <.025) diminished slope of the systolic stress-strain relation under isovolumic conditions of the left ventricle, was found in 110-week-old SHR, and it could be prevented by lisinopril treatment. Thus, long-term angiotensin-converting enzyme inhibition with lisinopril normalized arterial pressure and LVH, reversed myocardial fibrosis, and improved abnormal myocardial diastolic stiffness in advanced hypertensive heart disease in SHR. In addition, systolic dysfunction of the left ventricle could be prevented. The fibrolytic response to lisinopril was at least partly due to enhanced collagen degradation by activation of tissue matrix metalloproteinase 1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Cited by
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation
Burstein, B., & Nattel, S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.064 · Cited by 1,242
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease
Brilla, C. G., Funck, R. C., & Rupp, H. (2000) · Circulation · doi:10.1161/01.cir.102.12.1388 · Cited by 649
Self-citation
Metadata
- Authors
- Brilla, C. G., Matsubara, L., & Weber, K. T.
- Venue
- Hypertension
- Published
- 1996-08
- Volume
- 28
- Issue
- 2
- Pages
- 269-275
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2127460345
- Cited by
- 188
- References
- 1
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.